These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7997539)

  • 21. FDG PET characterization of renal masses: preliminary experience.
    Goldberg MA; Mayo-Smith WW; Papanicolaou N; Fischman AJ; Lee MJ
    Clin Radiol; 1997 Jul; 52(7):510-5. PubMed ID: 9240703
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma.
    Gritters LS; Francis IR; Zasadny KR; Wahl RL
    J Nucl Med; 1993 Sep; 34(9):1420-7. PubMed ID: 8355058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET.
    Adler LP; Crowe JP; al-Kaisi NK; Sunshine JL
    Radiology; 1993 Jun; 187(3):743-50. PubMed ID: 8497624
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Positron emission tomography of thyroid masses.
    Adler LP; Bloom AD
    Thyroid; 1993; 3(3):195-200. PubMed ID: 8257858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose.
    Steinert HC; Huch Böni RA; Buck A; Böni R; Berthold T; Marincek B; Burg G; von Schulthess GK
    Radiology; 1995 Jun; 195(3):705-9. PubMed ID: 7753998
    [TBL] [Abstract][Full Text] [Related]  

  • 26. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer.
    Bares R; Klever P; Hauptmann S; Hellwig D; Fass J; Cremerius U; Schumpelick V; Mittermayer C; Büll U
    Radiology; 1994 Jul; 192(1):79-86. PubMed ID: 8208970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of chest masses by FDG positron emission tomography.
    Hübner KF; Buonocore E; Singh SK; Gould HR; Cotten DW
    Clin Nucl Med; 1995 Apr; 20(4):293-8. PubMed ID: 7788982
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoplasms in a pediatric population: 2-[F-18]-fluoro-2-deoxy-D-glucose PET studies.
    Shulkin BL; Mitchell DS; Ungar DR; Prakash D; Dole MG; Castle VP; Hernandez RJ; Koeppe RA; Hutchinson RJ
    Radiology; 1995 Feb; 194(2):495-500. PubMed ID: 7824731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET.
    Minn H; Zasadny KR; Quint LE; Wahl RL
    Radiology; 1995 Jul; 196(1):167-73. PubMed ID: 7784562
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose.
    Patz EF; Lowe VJ; Hoffman JM; Paine SS; Harris LK; Goodman PC
    Radiology; 1994 May; 191(2):379-82. PubMed ID: 8153309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Triple-head SPECT with 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG): initial evaluation in oncology and comparison with FDG PET.
    Macfarlane DJ; Cotton L; Ackermann RJ; Minn H; Ficaro EP; Shreve PD; Wahl RL
    Radiology; 1995 Feb; 194(2):425-9. PubMed ID: 7824722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT.
    Newman JS; Francis IR; Kaminski MS; Wahl RL
    Radiology; 1994 Jan; 190(1):111-6. PubMed ID: 8259386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adrenal masses in patients with cancer: PET/CT characterization with combined CT histogram and standardized uptake value PET analysis.
    Perri M; Erba P; Volterrani D; Guidoccio F; Lazzeri E; Caramella D; Mariani G
    AJR Am J Roentgenol; 2011 Jul; 197(1):209-16. PubMed ID: 21701032
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pulmonary abnormalities and PET data analysis: a retrospective study.
    Lowe VJ; Duhaylongsod FG; Patz EF; Delong DM; Hoffman JM; Wolfe WG; Coleman RE
    Radiology; 1997 Feb; 202(2):435-9. PubMed ID: 9015070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
    Wu ZJ; Zhang YX; Wei H; Jia Q
    Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cancer screening with whole-body FDG PET].
    Yasuda S; Ide M; Takagi S; Shohtsu A
    Kaku Igaku; 1996 Oct; 33(10):1065-71. PubMed ID: 8952258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose.
    Wahl RL; Cody RL; Hutchins GD; Mudgett EE
    Radiology; 1991 Jun; 179(3):765-70. PubMed ID: 2027989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial.
    Buchmann I; Reinhardt M; Elsner K; Bunjes D; Altehoefer C; Finke J; Moser E; Glatting G; Kotzerke J; Guhlmann CA; Schirrmeister H; Reske SN
    Cancer; 2001 Mar; 91(5):889-99. PubMed ID: 11251940
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy.
    Lowe VJ; DeLong DM; Hoffman JM; Coleman RE
    J Nucl Med; 1995 May; 36(5):883-7. PubMed ID: 7738668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.